The protocol at a glance
In the COVID-19 trial, 10 mg of thymalin was injected into the muscle once a day for 10 days, on top of standard care.
| Trial | Amount and schedule |
|---|---|
| Severe COVID-19, older adults (80 people) | 10 mg in 2 mL of saline, injected into muscle, once a day for 10 days |
Kuznik B et al. Adv Gerontol 2021 (registered in Russia as LS-000267). Randomised, single-blind, one hospital (Chita, Russia). The control group got standard care plus a saline injection.
We note the published schedule of 10 mg into the muscle daily for 10 days. This came from the COVID-19 trial.
What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.
Mixing calculator
Enter the vial size, the water you add and the amount you want to draw; it gives the mark on a 100-unit (1 mL) insulin syringe.
What the trials found
Single-centre trial, 80 older adults with severe COVID-19: 36 got thymalin, 44 got placebo. What was measured: deaths in hospital and clinical improvement.
Kuznik B et al. Adv Gerontol 2021;11(4):368-376 (PMC8654498). Mortality and improvement differences both had p = 0.039. One author, V. Khavinson, is a long-time developer of thymalin research.
Side effects
- The authors state thymalin has no side effects in older adults, but the trial paper gives little safety detail.
- Long-term safety outside Russian studies is not established.
How it works
Short peptides that act on genes
The authors link thymalin's effect to short peptides in it (KE, EW and EDP) that can bind DNA and histones and change which genes are active.
Sources
- Kuznik B et al. Adv Gerontol 2021 (Peptide drug thymalin, severe COVID-19), PMC8654498
- Khavinson VKh et al. Neuro Endocrinol Lett 2003 (266 older adults, 6-8 years), PMID 14523363
- Drugs@FDA / openFDA search: no thymalin product